ArticleAbdominal radiology (New York)2026
Periportal hyperintensity sign on Gd-BOPTA-enhanced hepatobiliary phase MRI identifies patients less likely to achieve recompensation in decompensated cirrhosis.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo determine the association between periportal hyperintensity sign from gadobenate dimeglumine (Gd-BOPTA)-enhanced hepatobiliary phase magnetic resonance imaging (MRI) and the occurrence of recompensation in patients with decompensated cirrhosis.
methodsThis retrospective study included 252 patients with decompensated cirrhosis who underwent Gd-BOPTA-enhanced MRI at the time of decompensation. The periportal hyperintensity sign in the hepatobiliary phase was documented. Recompensation was defined using modified Baveno VII criteria. Cox proportional hazards regression was used to evaluate the association between the periportal hyperintensity sign and recompensation. Sensitivity analyses and bootstrap resampling were performed to test the robustness of the results. Survival outcomes were explored according to recompensation status.
resultsOf the 252 patients, 37 (14.7%) exhibited the periportal hyperintensity sign. Linear regression revealed that the periportal hyperintensity sign was significantly associated with a higher model for end-stage liver disease (MELD)-Na score (coefficient, 2.90; 95% confidence interval [CI], 1.00-4.81; p = 0.003). Eighty patients (31.7%) achieved recompensation after a median follow-up of 44.7 months (interquartile range, 16.9-73.7 months). Among the 37 patients with the periportal hyperintensity sign, 3 patients (8.1%) achieved recompensation. Periportal hyperintensity was independently associated with a lower probability of recompensation (hazard ratio, 0.17; 95% CI, 0.05-0.49; p = 0.004), and the association was directionally consistent across sensitivity analyses. Patients without the periportal hyperintensity sign demonstrated a significantly higher cumulative incidence of recompensation than those exhibiting the sign (p = 0.0029). Survival curves indicated significant differences between the recompensated and non-recompensated groups (p < 0.0001).
conclusionsPeriportal hyperintensity sign from Gd-BOPTA-enhanced hepatobiliary phase MRI may help identify patients less likely to achieve recompensation in decompensated cirrhosis.
Indexed as
Identifiers
42455326What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.